Literature DB >> 7509772

Immunohistochemical study of hepatic fibrosis induced in rats by multiple galactosamine injections.

A M Jonker1, F W Dijkhuis, M J Hardonk, P Moerkerk, J Ten Kate, J Grond.   

Abstract

Multiple injections of D-galactosamine induce liver fibrosis and cirrhosis in rats. The purpose of this immunopathological study was to correlate inflammation and hepatic extracellular matrix remodeling after repeated administration of galactosamine. Rats were given 10, 20, 30, 40, 60, 80, 100 and 140 intraperitoneal injections of D-galactosamine (500 mg/kg body wt, three times weekly). Controls received injections of saline solution. Cryostat sections of liver tissue obtained on biopsy or autopsy were immunostained with a panel of monoclonal and polyclonal monospecific antibodies reactive with macrophages, T and B lymphocytes, desmin, the extracellular matrix components fibronectin; laminin; collagen types I, III and IV; and the fibronectin receptor alpha 5 beta 1. Total RNA was extracted and Northern-blot analysis was performed with a specific cDNA probe for rat collagen type III. Spotty liver cell necrosis and mild portal and parenchymal inflammation was seen after 10 injections of galactosamine. After 20 to 40 injections, expansion of protal tracts, prominent bile ductular proliferation and gradual formation of fibrous septa were encountered with the development of cirrhosis at later intervals. These progressive histological changes were paralleled by a gradual increase of desmin-positive cells in developing septa with deposition of fibronectin; collagen types I, III, and IV; and laminin. Northern-blot analysis showed that this accumulation of extracellular matrix was not accompanied by increase of mRNA for collagen type III. In conclusion, repetitive administration of galactosamine causes progressive liver disease with prominent bile ductule proliferation and development of fibrous septa. These pathological alterations bear some resemblance to the morphological changes in chronic biliary disease in human beings.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509772     DOI: 10.1002/hep.1840190334

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

2.  Serum hyaluronate in patients with acute and fulminant hepatitis.

Authors:  K Suzuki; R Endo; Y Takikawa; I Nakadate; S Sato
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

3.  Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis.

Authors:  Baixue Zheng; Looling Tan; Xuejun Mo; Weimiao Yu; Yan Wang; Lisa Tucker-Kellogg; Roy E Welsch; Peter T C So; Hanry Yu
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

Review 4.  Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development.

Authors:  Bénédicte Delire; Peter Stärkel; Isabelle Leclercq
Journal:  J Clin Transl Hepatol       Date:  2015-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.